Allele frequency of CYP2C19 in a Portuguese population

Pharmacogenetics

Volumn 7, Issue 4, 1997, Pages 333-335

  Ruas, Jorge Lira ^a,b   Lechner, Maria Celeste ^a,b  

^a INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^b RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

CYP2C19; Genotype; Human cytochrome P450; Polymorphism; Portuguese

Indexed keywords

CYTOCHROME P450 ISOENZYME;

ALLELE; ARTICLE; CONTROLLED STUDY; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PORTUGAL; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ARYL HYDROCARBON HYDROXYLASES; CHILD; CYTOCHROME P-450 ENZYME SYSTEM; GENE FREQUENCY; GENOTYPE; HUMANS; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PORTUGAL; RANDOM ALLOCATION;

EID: 0012887670     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199708000-00009     Document Type: Article

References (19)

1. Brockmóller J, Rost KL, Schenkel A, Roots I. Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon 5 G→A splice mutation. Pharmacogenetics 1995: 5. 80-88.
2. Brosen K, de Morais SM, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 1995: 5. 312-317.
3. Chang M, Dahl M-L, Tybring G, Gótharson E, Bertilsson L. Use of omeprazole as a probe for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotypeand CYT2C19 genotype. Pharmacogenetics 1995: 5. 358-363.
4. Choonara IA, Cholerton S, Haynes BP, Breckenbridge AM, Park BK. Stereoselective interaction between the R-enantiomer of warfarin and cimetidine. Br J Clin Pharmacol 1986: 21. 271-277.
5. Daly AK, Brockmóller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang J-D, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996: 6. 193-201.
6. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin in humans. J Biol Chem 1994a: 22. 15419-15422.
7. de Morals SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994b: 46. 594-598.
8. Estabrook CB, Estabrook GF. ACTUS: a solution to the problem of small samples in the analysis of two-way contingency tables. Historical Methods 1989: 22. 5-8.
9. Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ, Idle JR. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirements in patients undergoing anticoagulation therapy. Pharmacogenetics 1995: 5. 389-392.
10. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily Pharmacogenetics 1994: 4. 285-299.
11. Gray IC, Nobile C, Muresu R, Ford S, Spurr NK. A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics 1995: 28. 328-332.
12. Innis MA, Gelfand DH. Optimization of PCRs. In: Innis MA, Gelfand OH, Sninsky JJ, White TJ, eds. PCR Protocols: A guide to methods and applications. London: Academic Press, 1990.
13. Jurima-Romet M, Goldstein JA, LeBelle M, Aubin RA, Foster BC, Walop W, Rode A. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inunit population. Pharmacogenetics 1996: 6. 329-339.
14. Kaminsky LS, de Morais SMF. Faletto MB, Dunbar DA, Goldstein JA. Correlation of human cytochrome P4502C substrate specificities with primary structure: Warfarin as a probe. Mol Pharmacol 1993: 43. 234-239.
15. Masimirembwa C, Bertilsson L, Johansson I, Hasler JA, Ingelman-Sundberg M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995: 57. 656-661.
16. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985: 38. 402-408.
17. Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA. Cloning and expression of complementary DNAs for multiple members of the human Cytochrome P45011C subfamily. Biochemistry 1991: 30. 3247-3255.
18. Rost KL, Roots I. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19. Hepatology 1996: 23. 1491-1497.
19. Takakubo F, Kuwano A, Kondo I. Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese. Pharmacogenetics 1996: 6. 265-267.